Noradrenergic modulation of subthalamic nucleus activity: Behavioral and electrophysiological evidence in intact and 6-hydroxydopamine-lesioned rats

Journal of Neuroscience

Volumn 27, Issue 36, 2007, Pages 9595-9606

  Belujon, Pauline ^a   Bezard, Erwan ^a   Taupignon, Anne ^a   Bioulac, Bernard ^a   Benazzouz, Abdelhamid ^a  

^a CNRS   (France)

Author keywords

6 hydroxydopamine; Extracellular recordings; Locomotor activity; Norepinephrine (noradrenergic); Parkinson's disease; Subthalamic nucleus

Indexed keywords

CIRAZOLINE; GUANABENZ; IDAZOXAN; OXIDOPAMINE; PRAZOSIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; BRAIN SLICE; CONTROLLED STUDY; DRUG EFFECT; ELECTROPHYSIOLOGY; HYPOKINESIA; IN VIVO STUDY; LOCOMOTION; MALE; NEUROMODULATION; NONHUMAN; PARKINSONISM; PATCH CLAMP; PRIORITY JOURNAL; RAT; SUBTHALAMIC NUCLEUS;

ADRENERGIC ALPHA-AGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANIMALS; BEHAVIOR, ANIMAL; ELECTROPHYSIOLOGY; HYPOKINESIA; IMMUNOHISTOCHEMISTRY; MALE; MEDIAL FOREBRAIN BUNDLE; MOTOR ACTIVITY; NEURONS; NOREPINEPHRINE; ORGAN CULTURE TECHNIQUES; OXIDOPAMINE; PARKINSONIAN DISORDERS; PATCH-CLAMP TECHNIQUES; RATS; RATS, WISTAR; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, ALPHA-2; SUBTHALAMIC NUCLEUS; SYNAPTIC TRANSMISSION;

EID: 34848863031     PISSN: 02706474     EISSN: 02706474     Source Type: Journal    
DOI: 10.1523/JNEUROSCI.2583-07.2007     Document Type: Article

References (82)

1. Alexander GE, Crutcher MD, DeLong MR (1990) Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Prog Brain Res 85:119-146.
2. Antonelli T, Morari M, Magri A, Bianchi C (1991) Effect of alpha-adrenoreceptors in the control of spontaneous motility and morphine withdrawal syndrome. Boll Soc Ital Biol Sper 67:965-971.
3. Arcos D, Sierra A, Nunez A, Flores G, Aceves J, Arias-Montano JA (2003) Noradrenaline increases the firing rate of a subpopulation of rat subthalamic neurones through the activation of alpha 1-adrenoceptors. Neuropharmacology 45:1070-1079.
4. Awad H, Hubert GW, Smith Y, Levey AI, Conn PJ (2000) Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J Neurosci 20:7871-7879.
5. Baron MS, Wichmann T, Ma D, DeLong MR (2002) Effects of transient focal inactivation of the basal ganglia in parkinsonian primates. J Neurosci 22:592-599.
6. Baufreton J, Garret M, Dovero S, Dufy B, Bioulac B, Taupignon A (2001) Activation of GABA(A) receptors in subthalamic neurons in vitro: properties of native receptors and inhibition mechanisms. J Neurophysiol 86:75-85.
7. 1) dopamine receptors potentiate burst-firing in neurons of the subthalamic nucleus by modulating an L-type calcium conductance. J Neurosci 23:816-825.
8. Benazzouz A, Gross C, Feger J, Boraud T, Bioulac B (1993) Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys. Eur J Neurosci 5:382-389.
9. Bergman H, Wichmann T, DeLong MR (1990) Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 249:1436-1438.
10. Bergman H, Wichmann T, Karmon B, DeLong MR (1994) The primate subthalamic nucleus. II. Neuronal activity in the MPTP model of parkinsonism. J Neurophysiol 72:507-520.
11. Beurrier C, Congar P, Bioulac B, Hammond C (1999) Subthalamic nucleus neurons switch from single-spike activity to burst-firing mode. J Neurosci 19:599-609.
12. Bezard E, Brefel C, Tison F, Peyro-Saint-Paul H, Ladure P, Rascol O, Gross CE (1999) Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey. Prog Neuropsychopharmacol Biol Psychiatry 23:1237-1246.
13. Bezard E, Dovero S, Prunier C, Ravenscroft P, Chalon S, Guilloteau D, Crossman AR, Bioulac B, Brotchie JM, Gross CE (2001) Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. J Neurosci 21:6853-6861.
14. Bogeso KP, Arnt J, Boeck V, Christensen AV, Hyttel J, Jensen KG (1988) Antihypertensive activity in a series of 1-piperazino-3-phenylindans with potent 5-HT2-antagonistic activity. J Med Chem 31:2247-2256.
15. Boraud T, Bezard E, Guehl D, Bioulac B, Gross C (1998) Effects of L-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey. Brain Res 787:157-160.
16. 3H]idazoxan in rat brain. J Pharmacol Exp Ther 241:1079-1091.
17. Brefel-Courbon C, Thalamas C, Peyro-Saint-Paul H, Senard J, Montastuc J, Rascol O (1998) alpha-2 adrenoceptor antagonists - a new approach to Parkinson's disease? CNS Drugs 10:189-207.
18. Canteras NS, Shammah-Lagnado SJ, Silva BA, Ricardo JA (1990) Afferent connections of the subthalamic nucleus: a combined retrograde and anterograde horseradish peroxidase study in the rat. Brain Res 513:43-59.
19. Chan-Palay V (1991) Alterations in the locus coeruleus in dementias of Alzheimer's and Parkinson's disease. Prog Brain Res 88:625-630.
20. Chan-Palay V, Asan E (1989) Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 287:373-392.
21. Chopin P, Colpaert FC, Marien M (1999) Effects of alpha-2 adrenoceptor agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J Pharmacol Exp Ther 288:798-804.
22. Colpaert FC (1987) Pharmacological characteristics of tremor, rigidity and hypokinesia induced by reserpine in rat. Neuropharmacology 26:1431-1440.
23. Colpaert FC, Degryse AD, Van Craenendonck HV (1991) Effects of an alpha 2 antagonist in a 20-year-old Java monkey with MPTP-induced parkinsonian signs. Brain Res Bull 26:627-631.
24. Convents A, Convents D, De Backer JP, De Keyser J, Vauquelin G (1989) High affinity binding of 3H rauwolscine and 3H RX781094 to alpha 2 adrenergic receptors and non-stereoselective sites in human and rabbit brain cortex membranes. Biochem Pharmacol 38:455-463.
25. Cragg SJ, Baufreton J, Xue Y, Bolam JP, Bevan MD (2004) Synaptic release of dopamine in the subthalamic nucleus. Eur J Neurosci 20:1788-1802.
26. DeLong MR (1990) Primate models of movement disorders of basal ganglia origin. Trends Neurosci 13:281-285.
27. Domino EF, Ni L, Colpaert F, Marien M (2003) Effects of (+/-)-idazoxan alone and in combination with L-DOPA methyl ester in MPTP-induced hemiparkinsonian monkeys. Receptors Channels 9:335-338.
28. 4 receptor-knock-out mice exhibit reduced exploration of novel stimuli. J Neurosci 19:9550-9556.
29. Ehringer H, Hornykiewicz O (1960) Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Klin Wochenschr 38:1236-1239.
30. Fornaguera J, Carey RJ, Huston JP, Schwarting RK (1994) Behavioral asymmetries and recovery in rats with different degrees of unilateral striatal dopamine depletion. Brain Res 664:178-188.
31. Forno LS (1996) Neuropathology of Parkinson's disease. J Neuropathol Exp Neurol 55:259-272.
32. Fozard JR, Mir AK, Middlemiss DN (1987) Cardiovascular response to 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) in the rat: site of action and pharmacological analysis. J Cardiovasc Pharmacol 9:328-347.
33. Gomez-Mancilla B, Bedard PJ (1993) Effect of nondopaminergic drugs on L-DOPA-induced dyskinesias in MPTP-treated monkeys. Clin Neuropharmacol 16:418-427.
34. Grenhoff J, North RA, Johnson SW (1995) alpha 1-adrenergic effects on dopamine neurons recorded intracellularly in the rat midbrain slice. Eur J Neurosci 7:1707-1713.
35. Gross CE, Boraud T, Guehl D, Bioulac B, Bezard E (1999) From experimentation to the surgical treatment of Parkinson's disease: prelude or suite in basal ganglia research? Prog Neurobiol 59:509-532.
36. Haapalinna A, Leino T, Heinonen E (2003) The alpha 2-adrenoceptor antagonist atipamezole potentiates anti-Parkinsonian effects and can reduce the adverse cardiovascular effects of dopaminergic drugs in rats. Naunyn Schmiedebergs Arch Pharmacol 368:342-351.
37. B receptors. J Neurosci 25:6304-6315.
38. Hallworth NE, Wilson CJ, Bevan MD (2003) Apamin-sensitive small conductance calcium-activated potassium channels, through their selective coupling to voltage-gated calcium channels, are critical determinants of the precision, pace, and pattern of action potential generation in rat subthalamic nucleus neurons in vitro. J Neurosci 23:7525-7542.
39. Hassani OK, Mouroux M, Feger J (1996) Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus. Neuroscience 72:105-115.
40. Henry B, Fox SH, Peggs D, Crossman AR, Brotchie JM (1999) The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-DOPA in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 14:744-753.
41. Kalkman HO, Neumann V, Tricklebank MD (1997) Clozapine inhibits catalepsy induced by olanzapine and loxapine, but prolongs catalepsy induced by SCH 23390 in rats. Naunyn Schmiedebergs Arch Pharmacol 355:361-364.
42. Kaneoke Y, Vitek JL (1996) Burst and oscillation as disparate neuronal properties. J Neurosci Methods 68:211-223.
43. Kass JI, Mintz IM (2006) Silent plateau potentials, rhythmic bursts, and pacemaker firing: three patterns of activity that coexist in quadristable subthalamic neurons. Proc Natl Acad Sci USA 103:183-188.
44. Lakhlani PP, Lovinger DM, Limbird LE (1996) Genetic evidence for involvement of multiple effector systems in alpha 2A-adrenergic receptor inhibition of stimulus-secretion coupling. Mol Pharmacol 50:96-103.
45. Langer SZ (1974) Presynaptic regulation of catecholamine release. Biochem Pharmacol 23:1793-1800.
46. Lavoie B, Parent A (1990) Immunohistochemical study of the serotoninergic innervation of the basal ganglia in the squirrel monkey. J Comp Neurol 299:1-16.
47. Llado J, Esteban S, Garcia-Sevilla JA (1996) The alpha 2-adrenoceptor antagonist idazoxan is an agonist at 5-HT1A autoreceptors modulating serotonin synthesis in the rat brain in vivo. Neurosci Lett 218:111-114.
48. Martinez-Price DL, Geyer MA (2002) Subthalamic 5-HT(1A) and 5-HT(1B) receptor modulation of RU 24969-induced behavioral profile in rats. Pharmacol Biochem Behav 71:569-580.
49. Mathe JM, Nomikos GG, Hildebrand BE, Hertel P, Svensson TH (1996) Prazosin inhibits MK-801-induced hyperlocomotion and dopamine release in the nucleus accumbens. Eur J Pharmacol 309:1-11.
50. Mavridis M, Colpaert FC, Millan MJ (1991) Differential modulation of (+)-amphetamine-induced rotation in unilateral substantia nigralesioned rats by alpha 1 as compared to alpha 2 agonists and antagonists. Brain Res 562:216-224.
51. Mehta A, Chesselet MF (2005) Effect of GABA(A) receptor stimulation in the subthalamic nucleus on motor deficits induced by nigrostriatal lesions in the rat. Exp Neurol 193:110-117.
52. Miklyaeva EI, Martens DJ, Whishaw IQ (1995) Impairments and compensatory adjustments in spontaneous movement after unilateral dopamine depletion in rats. Brain Res 681:23-40.
53. Mizuno Y, Kondo T, Mori H (1994) Various aspects of motor fluctuations and their management in Parkinson's disease. Neurology 44:S29-S34.
54. Molderings GJ, Fink K, Schlicker E, Gothert M (1987) Inhibition of noradrenaline release via presynaptic 5-HT1B receptors of the rat vena cava. Naunyn Schmiedebergs Arch Pharmacol 336:245-250.
55. Mori S, Takino T, Yamada H, Sano Y (1985) Immunohistochemical demonstration of serotonin nerve fibers in the subthalamic nucleus of the rat, cat and monkey. Neurosci Lett 62:305-309.
56. Narabayashi H (1983) Pharmacological basis of akinesia in Parkinson's disease. J Neural Transm Suppl 19:143-151.
57. Ni Z, Bouali-Benazzouz R, Gao D, Benabid AL, Benazzouz A (2001a) Intrasubthalamic injection of 6-hydroxydopamine induces changes in the firing rate and pattern of subthalamic nucleus neurons in the rat. Synapse 40:145-153.
58. Ni Z, Gao D, Bouali-Benazzouz R, Benabid AL, Benazzouz A (2001b) Effect of microiontophoretic application of dopamine on subthalamic nucleus neuronal activity in normal rats and in rats with unilateral lesion of the nigrostriatal pathway. Eur J Neurosci 14:373-381.
59. Ni ZG, Bouali-Benazzouz R, Gao DM, Benabid AL, Benazzouz A (2001c) Time-course of changes in firing rates and firing patterns of subthalamic nucleus neuronal activity after 6-OHDA-induced dopamine depletion in rats. Brain Res 899:142-147.
60. Otsuka T, Murakami F, Song WJ (2001) Excitatory postsynaptic potentials trigger a plateau potential in rat subthalamic neurons at hyperpolarized states. J Neurophysiol 86:1816-1825.
61. Parent A, Hazrati LN (1995) Functional anatomy of the basal ganglia. II. The place of subthalamic nucleus and external pallidum in basal ganglia circuitry. Brain Res Brain Res Rev 20:128-154.
62. Parent A, Cote PY, Lavoie B (1995) Chemical anatomy of primate basal ganglia. Prog Neurobiol 46:131-197.
63. Paxinos G, Watson C (1996) The rat brain in stereotatic coordinates. San Diego: Academic.
64. Pompeiano M, Palacios JM, Mengod G (1994) Distribution of the serotonin 5-HT2 receptor family mRNAs: comparison between 5-HT2A and 5-HT2C receptors. Brain Res Mol Brain Res 23:163-178.
65. Rascol O, Arnulf I, Peyro-Saint Paul H, Brefel-Courbon C, Vidailhet M, Thalamas C, Bonnet AM, Descombes S, Bejjani B, Fabre N, Montastruc JL, Agid Y (2001) Idazoxan, an alpha-2 antagonist, and L-DOPA-induced dyskinesias in patients with Parkinson's disease. Mov Disord 16:708-713.
66. Sastre-Coll A, Esteban S, Garcia-Sevilla JA (1999) Effects of imidazoline receptor ligands on monoamine synthesis in the rat brain in vivo. Naunyn Schmiedebergs Arch Pharmacol 360:50-62.
67. Scheer A, Costa T, Fanelli F, De Benedetti PG, Mhaouty-Kodja S, Abuin L, Nenniger-Tosato M, Cotecchia S (2000) Mutational analysis of the highly conserved arginine within the Glu/Asp-Arg-Tyr motif of the alpha(1b)-adrenergic receptor: effects on receptor isomerization and activation. Mol Pharmacol 57:219-231.
68. Sommermeyer H, Frielingsdorf J, Knorr A (1995) Effects of prazosin on the dopaminergic neurotransmission in rat brain. Eur J Pharmacol 276:267-270.
69. Stanford IM, Kantaria MA, Chahal HS, Loucif KC, Wilson CL (2005) 5-Hydroxytryptamine induced excitation and inhibition in the subthalamic nucleus: action at 5-HT(2C), 5-HT(4) and 5-HT(1A) receptors. Neuropharmacology 49:1228-1234.
70. Starke K (1972) Influence of extracellular noradrenaline on the stimulation-evoked secretion of noradrenaline from sympathetic nerves: evidence for a receptor-mediated feed-back inhibition of noradrenaline release. Naunyn Schmiedebergs Arch Pharmacol 275:11-23.
71. Starke K, Montel H, Gayk W, Merker R (1974) Comparison of the effects of clonidine on pre- and postsynaptic adrenoceptors in the rabbit pulmonary artery. alpha-Sympathomimetic inhibition of neurogenic vasoconstriction. Naunyn Schmiedebergs Arch Pharmacol 285:133-150.
72. Stern Y, Mayeux R, Cote L (1984) Reaction time and vigilance in Parkinson's disease. Possible role of altered norepinephrine metabolism. Arch Neurol 41:1086-1089.
73. Tai CH, Boraud T, Bezard E, Bioulac B, Gross C, Benazzouz A (2003) Electrophysiological and metabolic evidence that high-frequency stimulation of the subthalamic nucleus bridles neuronal activity in the subthalamic nucleus and the substantia nigra reticulata. FASEB J 17:1820-1830.
74. Vauquelin G, De Backer JP, Ladure P, Flamez A (1999) Identification of I1 and I2 imidazoline receptors in striatum membranes from different species. Ann NY Acad Sci 881:135-143.
75. Villegier AS, Drouin C, Bizot JC, Marien M, Glowinski J, Colpaert F, Tassin JP (2003) Stimulation of postsynaptic alpha1b- and alpha2-adrenergic receptors amplifies dopamine-mediated locomotor activity in both rats and mice. Synapse 50:277-284.
76. Wang L, Kitai ST, Xiang Z (2006) Activity-dependent bidirectional modification of inhibitory synaptic transmission in rat subthalamic neurons. J Neurosci 26:7321-7327.
77. Wang R, Macmillan LB, Fremeau Jr RT, Magnuson MA, Lindner J, Limbird LE (1996) Expression of alpha 2-adrenergic receptor subtypes in the mouse brain: evaluation of spatial and temporal information imparted by 3 kb of 5′ regulatory sequence for the alpha 2A AR-receptor gene in transgenic animals. Neuroscience 74:199-218.
78. Wellman PJ, Davies BT (1992) Effects of the alpha 1-adrenergic agonist cirazoline on locomotion and brown adipose tissue thermogenesis in the rat. Life Sci 50:1745-1753.
79. Xiang Z, Wang L, Kitai ST (2005) Modulation of spontaneous firing in rat subthalamic neurons by 5-HT receptor subtypes. J Neurophysiol 93:1145-1157.
80. Yamazaki M, Tanaka C, Takaori S (1979) Significance of central noradrenergic system on harmaline induced tremor. Pharmacol Biochem Behav 10:421-427.
81. Zhu ZT, Munhall A, Shen KZ, Johnson SW (2004) Calcium-dependent subthreshold oscillations determine bursting activity induced by N-methyl-D-aspartate in rat subthalamic neurons in vitro. Eur J Neurosci 19:1296-1304.
82. Zhu ZT, Munhall A, Shen KZ, Johnson SW (2005) NMDA enhances a depolarization-activated inward current in subthalamic neurons. Neuropharmacology 49:317-327.